Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses

For Yolanda Justal, APRN, of the University of Miami Sylvester Comprehensive Cancer Center, the Aug. 26 FDA approval of daraxonrasib (Rasonque; Revolution Medicines, Inc.) brought profound professional validation. Justal, who managed patients on the pivotal Phase 3 RASolute 302 trial, watched clinical turnarounds she had rarely seen in her career. "[The] approval just culminated all of our hard work," Justal reflected in an interview with Oncology Nursing News. "The excitement had been building as we were enrolling patients and noticing they were faring better, having better quality of lives, and living longer."

The once-daily 300 mg oral tablet was approved 6.5 months ahead of schedule for adults with metastatic pancreatic adenocarcinoma who progressed on at least one prior systemic therapy or are not candidates for multiagent chemotherapy. Historically, targeting the RAS pathway—mutated in over 90% of cases—was believed to be undruggable. Daraxonrasib overcomes this by acting as a molecular glue to bind directly to the active, GTP-bound state of mutant and wild-type RAS, locking the growth driver in an off position.

While clinical sites celebrated, investigators swiftly emphasized the clinical reality of this breakthrough. Paul E. Oberstein, MD, assistant director of the Pancreatic Cancer Center at NYU Langone's Perlmutter Cancer Center and Section Chief of GI Oncology, shared this sense of gratification but offered a balanced perspective in an interview with Oncolgy Nursing News.

"Having achieved this milestone for patients is remarkable," Oberstein stated. "Daraxonrasib is a remarkable drug—but it didn't cure people yet, right? So, it prolonged survival. It helped improve quality of life, but it did not yet result in cures." Because of this, "we really have to use every tool in our toolkit, everything in our armamentarium to fight pancreatic cancer, and [daraxonrasib] is going to be an essential tool in that kit for almost every patient with advanced cancer."

This transition from clinic infusion chairs to self-administered home tablets places advanced practice providers (APPs), physician assistants (PAs), and oncology nurses at the center of clinical care coordination. "Their role is going to be essential," Oberstein emphasized. "The better the therapies are, the more broadly we can give them, the more we're going to have to manage the side effects. The only way you're going to get a therapy to work is by giving it to people. So, if we can't manage the side effect and be able to keep people on drug, it's not going to help them."

Deciphering the Evidence: Efficacy Outcomes From RASolute 302

To effectively counsel patients, oncology nursing teams must be fluent in the clinical data supporting the FDA's expedited approval. This approval was based on the global Phase 3 RASolute 302 trial (NCT06625320), which randomized 500 adults with previously treated metastatic pancreatic adenocarcinoma to receive oral daraxonrasib (300 mg once daily) or standard chemotherapy. The trial met all endpoints, nearly doubling survival:

• Survival & Progression: In the ITT population, patients on daraxonrasib achieved a median OS of 13.2 months vs. 6.7 months with chemotherapy (HR, 0.40; p<0.0001). Results were consistent in the RAS G12-mutated subpopulation (13.2 vs. 6.6 months). Median PFS was 7.2 months with daraxonrasib vs. 3.6 months with chemotherapy (HR, 0.49; p<0.0001).
• Quality of Life & Pain: Daraxonrasib significantly delayed the time to deterioration (TTD) of global health status and quality of life, with a median TTD of 5.7 months vs. 2.6 months for chemotherapy (HR, 0.60; p<0.001). Worsening of pain was delayed to a median of 9.2 months with daraxonrasib vs. 3.8 months with chemotherapy (HR, 0.51; p<0.001).

"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease," said Memorial Sloan Kettering Cancer Center gastrointestinal oncologist Eileen O'Reilly, MD, lead author of The New England Journal of Medicine’s publication of the trial’s findings, in a statement. Because the drug directly shuts down mutant signaling, patients usually feel the difference quite quickly, O'Reilly noted.

Reviewing these benefits, Oberstein noted the unique advantage of this oral therapy in a highly symptomatic patient population. "Pancreas cancer is tough to treat, partly because the targets are difficult, but partly because patients are very sick and it's hard to stress them too much," Oberstein explained. "And so, one of the benefits here is that this medication is very broadly available, meaning smaller pills, there's very few reasons why someone couldn't take it. And so potentially, not everyone's going to benefit the same way, but many people are going to benefit even if they have quite symptomatic issues, and it can improve their quality of life or delay deterioration substantially."

A Paradigm Shift: Shifting Safety Monitoring from Clinic to Home

Self-administered oral once-daily tablets move treatment outside outpatient centers, transferring primary safety monitoring directly to patients and caregivers at home. Oral oncology therapies do not reduce the need for meticulous clinical oversight; instead, they require a proactive reorganization of nursing triage.

"Oral therapy moves treatment outside of your infusion chairs and your infusion centers, but it's not going to reduce the need for clinical oversight," Justal explained.

Oberstein agreed that transition pathways require exhaustive coordination. "Obviously the best thing is education. You've got to know what to anticipate. You've got to be ready for it," Oberstein urged. "We develop quite extensive algorithms of both prophylactic medications and in response to toxicity."

To manage this shift safely, clinical teams must implement a structured, multi-step care workflow:

• Baseline Assessments: Establish clinical baselines for skin, oral mucosa, GI habits, and functional status prior to the patient's first dose.
• Written Instructions: Provide patients with clear written action plans highlighting which symptoms are manageable at home, which require a routine phone call, and which require emergency room evaluation.
• Early Contact & Portal Monitoring: Schedule proactive phone follow-ups within the first 7 to 14 days of therapy when early-stage toxicities are most likely to emerge. Encourage patients to upload photographs of skin changes or rashes via secure portal messaging for immediate, remote clinical evaluation.
• Standardized Clinic Workflows: Train triaging staff on a defined pathway using CTCAE grading so that calls are documented consistently.

Dosing Parameters, Compliance Windows, and Patient Adherence

The standard dose of daraxonrasib is a 300 mg tablet taken orally once daily, with or without food. "Draxonrasib is just dosed once a day," noted Memorial Sloan Kettering clinical trials nurse Mary Larsen, MSN, RN, OCN, in an interview with Oncology Nursing News. "There's a pretty wide window—we tell patients it could be up to 4 hours earlier or 4 hours later." This 8-hour daily compliance window provides generous lifestyle flexibility.

However, oral administration introduces compliance risks. Larsen observed that "patients are home; they kind of will do what they think is best, but sometimes they'll tell us what they did instead of asking us what to do." To track compliance and prevent uncommunicated dose adjustments, clinical teams must employ targeted compliance strategies:

• Pill Diaries & Smartphone Alarms: Send patients home with a physical pill diary to track the exact timing of each dose and encourage dedicated smartphone timers and reminder apps.
• Caregiver Engagement & Direct Inquiry Workflows: Actively involve family members in the compliance process and ensure that clinic staff ask direct, non-judgmental questions about missed or delayed doses during every encounter.

"We make our dosing instructions very specific," Justal said. "Patients are to take daraxonrasib once daily at about the same time each day. They are not to hold any doses, reduce, double up for missed doses, or adjust the number of pills they are taking without first contacting us. During every contact with the patient, we should be asking the patient about any missed doses because that helps us to identify compliance issues."

Proactive Management of Signature Toxicities

While daraxonrasib lacks the systemic myelosuppressive profile of cytotoxic chemotherapy, it causes distinct, localized toxicities. Oberstein observed, "people should learn about what this drug does. It definitely causes a rash that's unique [and] causes mouth sores which we have to treat."

1. Dermatologic Toxicity (86% Overall; 10% Grade 3)

Dermatologic toxicities occurred in 86% of patients. "Prophylaxis should be prescribed and reviewed with the patient before they even take that first dose," Justal stated. "We don't wait until after the rash develops."

The prophylactic skin regimen requires a highly coordinated, multi-agent protocol initiated before the first dose:

• Topical Steroids & Emollients: Apply a mild topical corticosteroid daily to the face and chest, and use thick, alcohol-free body emollient creams daily to maintain skin barrier moisture.
• Photoprotection & Sunscreen: Instruct patients to strictly limit sun exposure and apply broad-spectrum sunscreen (SPF 30 or higher) daily, as UV light exacerbates the rash.
• Systemic Antibiotics: Prescribe prophylactic oral antibiotics (typically doxycycline or minocycline) to mitigate inflammatory skin reactions.

Nursing teams must actively counsel patients through the side effects of these prophylactic antibiotics, which can cause mild GI upset. "Sometimes patients don't want to take the antibiotic if they are also getting some GI upset from the daraxonrasib, because they feel like the daraxonrasib is more important," Larsen noted. Nurses must reinforce that pre-emptive antibiotics are critical to preventing a severe, emotionally distressing facial rash that can bleed, break down, and ultimately lead to treatment disruption.

"We use our electronic messaging system where our patients can actually take a picture of any rash or changes to the skin that they're able to upload and send to the treatment team to help us further identify what things require a more immediate assessment," Justal added.

2. Stomatitis and Oral Disorders (57% Overall; 9% Grade 3)

Stomatitis occurs in 57% of patients. Because maintaining nutritional intake is a primary challenge in advanced pancreatic cancer, oral care is a nursing priority. "For sure, for stomatitis we recommend frequent oral assessments, and that's done in clinic as well as routine dentist visits to protect and preserve the oral mucosa," Justal advised.

Nurses must instruct patients to maintain ultra-soft toothbrushing twice daily, floss daily, and initiate routine saltwater or baking soda mouth rinses. Clinical teams should prescribe a steroid-containing mouth rinse (such as dexamethasone) at baseline. Justal emphasized that patients are instructed to use this up to three times a day as needed, making sure that they swish for at least two minutes, and then spit out the mouthwash. Nurses must monitor patients' weight weekly and track fluid intake to catch nutritional or hydration decline early.

3. Gastrointestinal Toxicities: Diarrhea (63% Overall) and Triaging Perforations (0.9% Overall)

Diarrhea is highly common, occurring in 63% of patients, and is typically most troublesome during the first few doses. "We send prescriptions for loperamide, which has to be available prior to beginning treatment," Justal stated. "We instruct the patient to use two capsules immediately after the first loose bowel movement." Patients should record their bowel habits and report immediately if diarrhea is unresponsive to standard loperamide.

Critically, nursing teams must educate patients on distinguishing common diarrhea from rare, life-threatening gastrointestinal perforations, which occurred in 0.9% of patients in clinical trials. "We educate the patient that they should immediately report any severe or worsening abdominal pain, pain that's accompanied with severe cramping, any blood in the stool or black, tarry stools, or an inability to have a bowel movement or to pass gas," Justal warned. "These are emergency red flags that need to be communicated with us immediately."

Destigmatizing Holds and Dose Reductions

Because pancreatic cancer has historically had so few targeted alternatives, patients may harbor fears surrounding treatment holds, worrying that taking a break will cause disease progression. Frontline nursing teams play an essential role in de-escalating this anxiety and destigmatizing therapeutic dose holds.

"I personally have never had a conversation with someone about possibly stopping the drug altogether because of side effects," Larsen shared. "A lot of people are having their cancer respond really well and they don't want to stop the pill even if side effects are bad. We're more convincing people to take a pause."

Larsen and Justal emphasized that temporary holds and dose reductions are planned, validated strategies. Across clinical trials, this approach successfully kept permanent discontinuations due to adverse events to 2.9%, with 0.8% discontinuing due to rash.

"I explain to our patients that a treatment hold doesn't mean that the treatment isn't going to work," Justal explained. "This is a planned strategy; this hold will help us minimize the number of side effects that you're having and it allows whatever systems are adversely affected time to recover. It's safer to hold the treatment than to force the patient to push through, because pushing through can lead to ultimately hospitalizations or permanent discontinuations."

Access Navigation, Biomarkers, and the Role of Genetic Sequencing

With the Associated Press reporting a retail price of approximately $39,800 for a one-month supply, financial navigation must begin the moment the clinician decides to prescribe daraxonrasib to prevent delays in treatment initiation.

"The prescription should be routed promptly to an authorized specialty pharmacy, and the team should begin the process of insurance verification and any prior authorizations simultaneously," Justal urged. To support this, APPs and nurses must ensure complete documentation of previous systemic regimens and clear clinical rationale to secure prior authorizations. For patients facing copay or deductible barriers, clinical teams can route referrals to Revolution Medicines' support program.

Furthermore, while the FDA's approved label does not require a companion diagnostic test, securing a comprehensive molecular profile remains clinical best practice. Oberstein explained that while patients can receive daraxonrasib without genetic testing, tumor profiling is essential for their long-term clinical journey.

"It's absolutely essential, if feasible, to get molecular information and tumor profiling in every patient with advanced pancreas cancer," Oberstein advised. "And that's not so they can receive [daraxonrasib], it's because patients will eventually become resistant to this medicine and they will need other therapies. The more we know about tumors—why you start and why they become resistant—the more we can give patients as therapeutic options. We currently have multiple clinical trials that are targeting specific mutations. If you don't know them, you can't put them on trial. So it is really important for patients to know their molecular profile."

Future Horizons: Combinations, Earlier Stages, and Evolving Evidence

Because daraxonrasib is currently a monotherapy indicated for previously treated metastatic disease, research is already moving rapidly into combinations and earlier settings. Active Phase 3 trials are evaluating daraxonrasib compared with standard chemotherapy in the adjuvant setting following surgery to prevent recurrence and in the first-line metastatic setting in combination with chemotherapy.

Oberstein cautioned that combining this oral therapy with other agents requires careful clinical trial validation. "It is an oral medication [that is] well tolerated, though there are certainly side effects," Oberstein noted. "It's not trivial. It's not automatic to say you could combine [it] with other medications.” He highlighted that Perlmutter Cancer Center and other global sites are actively evaluating combinations with PRMT5 inhibitors, low-dose chemotherapy, or radiation. Oberstein also pointed to the exciting development of "allele-specific or targeted RAS inhibitors," which are designed to target single mutated forms of KRAS (such as KRAS G12D) rather than acting as a pan-RAS inhibitor like daraxonrasib. "Those actually look like they're easier to combine with chemotherapy, and we have multiple ongoing clinical trials looking at chemo plus those other inhibitors," he explained. "Combinations are coming, but they need to be tested and validated."

To keep pace with this science, oncology nursing education must be continuous. "Nursing education has to evolve with the evidence," Justal said. "Our teams should stay familiar with active clinical trials. We should be introducing clinical trials to our patients as one possible treatment option, and not necessarily as a last resort."

The FDA approval of daraxonrasib is a milestone in oncology, transforming a growth driver into a potentially treatable therapeutic target. By nearly doubling patient survival and preserving global quality of life, this could provide hope for patients facing advanced pancreatic cancer.

Yet, it is not a cure. The true potential of this therapy depends on the frontline expertise of the oncology care team. By establishing pre-emptive toxicity algorithms, coordinating meticulous oral and skin care prophylaxis, monitoring compliance, and guiding patients through strategic, safe treatment holds, oncology nurses, APPs, and PAs can translate clinical trial data into prolonged lives.

References

O'Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325-337. doi:10.1056/NEJMoa2605555

U.S. Food and Drug Administration. FDA approves first in class targeted therapy for metastatic pancreatic cancer. FDA News Release. Published August 26, 2026. Accessed August 27, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer

Revolution Medicines, Inc. U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer. Press Release. Published August 26, 2026. Accessed August 27, 2026. https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib

Perrone M, Neergaard L. FDA approves landmark pancreatic cancer drug that's shown to improve survival. AP News. Published August 26, 2026. Accessed August 27, 2026. https://apnews.com/article/pancreatic-cancer-drug-fda-approval-rasonque-03e437bfb8d728ec2a73b142cf8ec2fe

RASONQUE (daraxonrasib) Prescribing Information. Redwood City, CA: Revolution Medicines, Inc.; August 2026.